Udvalget for humanmedicinske lægemidler (CHMP) besluttede, at fordelene ved CYSTAGON var større end risiciene og anbefalede derfor udstedelse af en markedsføringstilladelse for CYSTAGON.
The Committee for Medicinal products for Human Use (CHMP) decided that CYSTAGON’ s benefits are greater than its risks and recommended that CYSTAGON be given marketing authorisation.